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Abstract
Osteosarcoma is rare and little improvement in survival rates has occurred in the last 25 years 
despite modern chemotherapeutic treatment. Bioluminescent cell lines for the modeling of 
osteosarcoma have shown success in tracking metastases in vivo, but commonly use adenoviral 
vectors to transfect the native cell line with bioluminescent reporters. The purpose of this study 
was to develop an orthotopic model for metastatic osteosarcoma capable of in vivo monitoring of 
metastatic and primary tumor burden in an immunocompetent mouse and compare that model to 
its wild type pathogenesis. K7M2 cells were transfected using a plasmid vector and were stable 
after 12 weeks. Thirty-four female BALB/c mice aged four to five weeks underwent orthotopic 
implantation of either wild type (n=12) or transfected (n=22) K7M2 cells in the proximal tibia. 
Mice were monitored for tumor growth and weekly In Vivo Imaging System (IVIS) imaging was 
performed to monitor for pulmonary metastasis. Although tumors developed sooner in the wild 
type group, no significant differences were seen compared to Transfected Group 1 in rate of 
inoculation, growth rates after first detection, metastatic rate, and time between inoculation and 
death. This study establishes a new murine model for metastatic osteosarcoma using the K7M2-wt 
cell line transfected with a non-viral plasmid luciferase vector. The benefits of this preclinical 
model include an intact immune system and orthotopically driven metastatic disease; this model 
appears comparable to its wild type counterpart. In the future, the model may be used to examine 
promising immunomodulatory therapies using bioluminescence in vivo.
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Primary osteosarcoma is rare and has an incidence of 800 new cases diagnosed yearly, with 
half of cases diagnosed in children.1 Five-year survival rate for localized disease is 60–80% 
and a dismal 15% with a metastatic presentation.2 Complete surgical resection with 
reconstruction in combination with neo-adjuvant and adjuvant chemotherapy is the mainstay 
of treatment. However, with the addition of modern chemotherapeutic agents, little progress 
has been made in patient survival rates in the past 25 years.
Multiple factors contribute to the difficulty of developing new therapies, including a low 
incidence of disease and rapid clinical course with the onset of metastasis. However, because 
of the poor survival outcomes, new treatment modalities are crucial. Immunotherapy is an 
innovative approach to treating osteosarcoma. Spurred by the observation that patients who 
develop post-operative infections have increased survivorship, the goal of immunotherapy is 
to harness the beneficial effects of a pro-inflammatory response while limiting destructive 
side effects.3–5 Most current murine models of osteosarcoma are insufficient to examine 
immunomodulation because the models use immunodeficient animals.6–10 In an attempt to 
study tumor burden and metastatic progression in vivo, a model of metastatic osteosarcoma 
in immunocompromised mice using the luciferase vector and bioluminescent imaging was 
recently established.11,12. However, the use of an orthotopic driven metastatic model in an 
immunocompetent model is needed.
Metastatic disease is of particular interest in osteosarcoma; the ability to monitor such 
progression is paramount in determining the efficacy of novel treatments. Methodologies 
that are currently available to detect disease in vivo include the use of micro computed 
tomography (micro CT) and magnetic resonance imaging (MRI). These modalities have 
high sensitivity to detect metastasis in murine models, with the lowest detection limits of 
600 um in the lungs.13 However, drawbacks include need for prolonged anesthesia to 
complete the scan partly because images are obtained between respirations to produce the 
best resolution. Further, machine capacity often allows for only one animal to be imaged at a 
time.
In osteosarcoma research, bioluminescent imaging has recently emerged as an important 
method for tracking both primary tumor burden and metastatic spread. It has the advantage 
of in vivo monitoring in live animals, precluding the need for euthanasia to survey metastasis 
and tumor burden. Its primary benefit is reduction in the number of animals required for in 
vivo studies.12,14,15 The in vivo imaging system (IVIS) quantifies flux produced by a 
reaction in which the luciferin substrate is oxidized by the luciferase enzyme. The gene for 
this enzyme can be transfected into the cancerous cell using plasmid vectors or viruses.
The purpose of this study was to develop an orthotopic model for metastatic osteosarcoma 
capable of in vivo monitoring of metastatic and primary tumor burden in an 
immunocompetent mouse and compare that model to its wild type pathogenesis. Most 
murine models consist of xenotransplants and have limited utility in examining the 
interactions among the host, the microenvironment, and the cancerous cells.16–19 In this 
syngeneic model, we used the highly metastatic K7M2-wt murine cell line transfected with 
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the luciferase gene and applied cells orthotopically to the tibiae of BALB/c mice. We 
followed the progression of the tumor and metastasis using IVIS and performed palliative 
amputations of the affected extremity; at euthanasia, metastatic tumor size was quantified 
and cross referenced with IVIS detection. These data were also compared to the wild type 
model to determine differences in inoculation rates, tumor growth rates, and metastatic rates.
Methods
Growth and preparation of transfected and wild type K7M2 cells
The K7M2 murine osteosarcoma cell line (ATCC CRL-2836, ATCC, Manassas, VA) was 
kindly donated by Dr. Kurt Weiss, MD (University of Pittsburgh Medical Center, Pittsburgh, 
PA) in April 2014. Mycoplasma testing is not routinely performed in our lab. The K7M2 cell 
line is derived by harvesting pulmonary metastases of the K7 murine osteosarcoma cell line, 
reimplanting the metastatic cells orthotopically and repeating the harvest of a pulmonary 
metastatic lesion. The cell line is considered highly aggressive with a reported pulmonary 
metastatic rate of over 90% in mice.
Wild Type (WT) K7M2 osteosarcoma cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 10% fetal bovine serum and 1% penicillin and streptomycin 
(Life Technologies, Carlsbad, CA) to obtain 75% confluency. The cells were washed with 
phosphate buffered saline (PBS) without calcium and magnesium (Corning Inc., Corning, 
NY) and harvested with Trypsin (0.25% Trypsin, 0.1% EDTA in HBSS w/o Calcium, 
Magnesium and Sodium Bicarbonate, Corning Inc.). The cell density was adjusted to one 
million cells (1.0 x 106) in 25 μL of PBS for inoculating mice. Passage one cells were used 
for orthotopic implantation.
Transfected K7M2 osteosarcoma cells were prepared by adding 1.0 ml (approximately 
3.0x105) WT cells into each well of a six-well plate containing 1.0 ml of DMEM containing 
10% fetal bovine serum and 1% penicillin and streptomycin. Cells were incubated at 37°C 
for 24 hours to obtain 75% confluency. A 3:1 transfection ratio complex was created using 
ViaFect Transfection reagent (Promega, Madison, WI) and pGL4.51 [luc2/CMV/Neo] 
plasmid vector (Promega) prepared per the manufacturer’s specifications and incubated with 
K7M2 cells for 24 hours. The cells were washed once with PBS, 2.0 ml of DMEM media 
was added to each well, and the cells were incubated for 48 hours at 37°C. The selective 
drug Geneticin-418 (Life Technologies) was then added to kill non-transfected cells. After 
further propagation, the cell density was adjusted to one million cells (1.0 x 106) in 25 μL of 
PBS for inoculating mice. Passage one transfected cells were used for orthotopic 
implantation.
Stability of transfected cell line
To assess if the luciferase reporter vector was stably passed to future generations, in vitro 
bioluminescence imaging was performed for 12 weeks. For this verification, 4.5 x 105 
transfected K7M2 cells were seeded in a 12-well plate, covered with media and incubated 
for 24 hours which created a final concentration of 5.0 x 105 cells per well. The media was 
removed just prior to imaging and 1.0 ml of 0.5 mM luciferin was added to each well. The 
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cells were imaged using the In Vivo Imaging System (IVIS) Lumina II with Living Image 
Software (PerkinElmer, Waltham, MA). Bioluminescent imaging was set to medium binning 
with an exposure time of five minutes.
Surgical implantation of K7M2 cells
All animal procedures were conducted in accordance with the Institutional Animal Care and 
Use Committee (IACUC). Thirty-four female BALB/c mice age four to five weeks were 
purchased from Jackson Laboratories (Bar Harbor, ME) and maintained in pathogen free 
animal housing facilities. A twelve-hour light/dark cycle was used, the animals were fed 
autoclaved chow, and had access to sterile water ad-libitum.
The Wild Type (WT) group (n = 12) underwent inoculation with wild type K7M2 cells. 
Transfected Group 1 (n = 10), Transfected Group 2 (n = 10), and Transfected Group 3 (n = 
2) were all inoculated with luciferase transfected K7M2 cells. Transfected Group 1 received 
intraperitoneal injection of luciferin only for tumor detection. Transfected Groups 2 and 3 
received both intraperitoneal and intranasal luciferin for tumor detection, along with shaving 
of the operative limb and chest prior to imaging.
The animal was weighed on a calibrated scale and placed into an anesthesia induction 
chamber. General anesthesia was induced using isofluorane (Piramal Enterprises Limited, 
Andhra Pradesh, India) with 100% oxygen at a rate of 2.5 liters/min until loss of the righting 
reflex occurred. The animal was then transferred to a heated operating stage, placed supine, 
and maintained under general anesthesia using a nasal cone at a rate of 2.5 L/min. 
Opthalamic lubricant was placed in both eyes and 0.02 ml of 1 mg/ml buprenorphine SR 
(Wildlife Pharmaceuticals, Windsor, CO) was injected subcutaneously using a 25 gauge 
needle.
The animal’s operative hind limb was prepped using betadine solution and sterilely draped. 
Using sterile technique, a small incision was made over the anterolateral leg under an 
operating microscope. Dissection was carried sharply to the tibia and directed proximally 
until the metaphyseal flair was identified. An 18 gauge needle was then used to create a 
small bore hole in the center of the tibia at the level of the proximal tibial flare. As soon as a 
small pilot hole was created, the needle was angled approximately 45° in the sagittal plane 
and advanced until the cortex was penetrated. The needle was twisted gently which caused 
the anterior flare/cortex to separate from the intact tibia, creating a cortical window. The 
posterior cortex remained intact to avoid a bicortical fracture. Twenty-five microliters of 
PBS containing one million K7M2 cells was then injected into the defect. The muscle was 
pulled back over the bone and the skin was closed in a running fashion using a 4-0 vicryl 
suture. Animals were awakened and recovered in the usual fashion.
Clinical monitoring of mice
Mice were monitored weekly until a visible tumor was appreciated after which they were 
measured daily using digital calipers (greatest width x by greatest length). Tumor volume 
was calculated using the formula V=(length x width2)/2. The mice were graded using our 
institution’s tumor burden scoring system weekly. This scoring system ranges from 0 to 60 
(0 = healthy animal; 60 = requires euthanasia) and is based on general appearance (fur, 
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mucus membranes, response to stimuli), body condition (well nourished, thin, cachectic), 
neurologic status (head tilt, bulging eyes, depression, self-mutilation, limb paralysis, 
seizures), tumor appearance (ulcerated, limits ability to ambulate, bleeding), and respiratory 
rate (normal, increased rate/effort, severe distress). After the elevation of any scoring 
variable, the animals were monitored daily and veterinary staff was consulted to ensure 
humane treatment and minimization of pain.
IVIS imaging
IVIS imaging uses a charge-coupled device camera that is able to detect light emitted from 
the luciferin-luciferase reaction within the tumor bed. Once a visibly detectable tumor was 
identified, animals were imaged weekly using the IVIS Lumina II with Living Image 
Software to monitor metastatic burden. After isoflurane induction, the animal was injected 
with luciferin (150 mg/kg) in the intraperitoneal cavity and placed onto the imaging 
platform, dorsal side up. Exposure varied between one and five minutes and 
bioluminescence binning was set to medium. Images were taken approximately five minutes 
post luciferin injection. After the first set of images was performed, the lower extremity (if 
present, see Tissue harvest below) was shielded for the second set of images. This method 
improves sensitivity for small lung tumors that are below the low threshold intensity 
obtained when a tumor is present in the limb (Figures 1a and 1b).
Intranasal luciferin
Ten BALB/c mice (Transfected Group 2) aged four to five weeks underwent inoculation 
with one million K7M2 cells according to the same protocol as mentioned above. These 
mice received 30 microliters of intranasal luciferin (150 mg/kg) in addition to the 
intraperitoneal luciferin as mentioned above. The operative extremity and chest of these 
mice were shaved prior to imaging. Otherwise, IVIS imaging settings, exposures, and 
images were taken in accordance with the protocol mentioned above. The purpose of this 
transfected group was to show improved IVIS sensitivity and earlier detection of pulmonary 
metastatic disease using intranasal luciferin.
Tumor luminescence over time
Two BALB/c mice (Transfected Group 3) aged four to five weeks underwent inoculation 
with one million K7M2 cells according to the same protocol as mentioned above. These 
mice received both intranasal and intraperitoneal luciferin according to the protocol 
mentioned above. The operative extremity of these mice was shaved prior to imaging. IVIS 
imaging settings, exposures, and images were taken in accordance with the above protocol. 
The purpose of this transfected group was to monitor luminescence and primary tumor size 
over time. Mice were imaged twice weekly until the tumor score reached 60, at which time 
the mice were euthanized.
Tissue harvest
Once the tumor reached sufficient volume (around 1.7 cm3), a palliative amputation of the 
affected hind limb was performed. The mouse was anesthetized and analgesic was provided 
as described previously. After prepping with betadine and sterile draping, a longitudinal 
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incision was made on the medial third of the tumor bed. The tumor was dissected away from 
the peritoneum, taking care not to violate the peritoneal cavity. The femoral vessels were 
identified along the medial tumor and traced toward the pelvis. Using 4-0 vicryl suture, the 
vessels were ligated just distal to the inguinal ligament. The hip was disarticulated from the 
pelvis by sharply incising the capsule, exposing the femoral head and dislocating it from the 
acetabulum with the tip of the scalpel. The limb was amputated by circumferentially 
dividing any remaining soft tissue attachments in line with the original incision. The skin 
edges were approximated and closed using a 4-0 vicryl suture in a running fashion. The 
animal was then awakened and recovered in the usual fashion.
Weekly IVIS imaging was continued (per above) until the tumor score reached 60 or at 16 
weeks post-inoculation. At this time, the mice were euthanized using carbon dioxide 
asphyxiation. The lungs were harvested en bloc and placed into a conical tube containing 
10% neutral buffered formalin (NBF). The specimens were delivered to the Pathology 
Laboratory for Translational Medicine, processed, and embedded per their protocol. The 
paraffin blocks were mounted on a microtome and 5 μm sections were obtained every 25 μm 
of sectioning until the entire specimen was exhausted. The slides were stained with 
hematoxylin and eosin. Slides were analyzed by one author (BG) as well as a board certified 
pathologist to confirm the presence of metastatic disease. The number of metastatic lesions 
was counted as well as the dimensions of the single largest tumor identified in the specimen.
Results
Stability of transfected cell line
There were no significant differences in radiance of the transfected cells at baseline and at 
12 weeks (3.93x106 p/sec/cm2 versus 9.71x106 p/sec/cm2). Linear regression modeling did 
not reveal significant differences in radiance of the transfected cells over time (R2=0.019, 
p=0.65).
Inoculation data of the wild type group
Twelve mice were inoculated (6 left limbs, 6 right limbs) with wild type K7M2 cells. The 
average mouse weight was 18.73 g (range 17.5 – 21.0) at time of inoculation. Eleven of 
twelve mice grew primary tumors at an average of 16.82 days (range 15 – 26) after cell 
implantation. One mouse died 15 days after the inoculation; no tumor growth was noted in 
this mouse. Eight mice underwent palliative amputation of their limb at an average of 12 
days (range 10 – 16) after first tumor sighting. Seven of eight survived the palliative 
amputation; one mouse died due to uncontrollable hemorrhage from the femoral vessels. 
Three mice did not undergo palliative amputation of their hind limb; these mice were 
euthanized at the time of primary tumor harvest. Average mouse weight was 23.58 g (range 
21.0 – 26.5) at time of amputation or early euthanasia and average tumor weight was 2.72 g 
(range 1.90 – 4.53). A primary recurrence of the tumor was noted in six of the eight mice. 
Five mice were euthanized at an average of 74 days (range 68 – 89) after inoculation for 
tumor scores of 60. All five of these mice had noted recurrent primary disease. Two mice 
were euthanized at 16 weeks post-inoculation in accordance with the study protocol; neither 
mouse demonstrated primary recurrence and both had a tumor score of 0 at time of 
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euthanasia. Three mice were euthanized at an average of 10.3 days (range 10 – 12) after first 
tumor sighting. At the time of euthanasia, lung specimens were collected on 10 mice (all 
eight that underwent palliative amputation and two mice euthanized at the time of primary 
tumor harvest) and processed for metastatic evaluation (see below).
Inoculation data for Transfected Group 1
Ten mice were inoculated (5 left limbs, 5 right limbs) with the luciferase transfected K7M2 
cells. The average mouse weight was 18.46 g (range 16.5 – 20.8) at the time of inoculation. 
Nine of the ten mice grew a primary tumor at an average of 35 days (range 27 – 55) after 
cell implantation. One mouse failed to develop a tumor; this mouse was euthanized eight 
weeks after inoculation. Six mice underwent palliative amputation of the affected hind limb 
an average of 11 days (range 9 – 18) after first tumor sighting. All mice survived the 
palliative amputation. Three mice did not undergo a palliative amputation of their affected 
limb; one mouse died during IVIS imaging prior to the procedure and two mice were 
euthanized at the time of primary tumor harvest rather than undergoing an amputation. The 
average mouse weight at time of amputation or early euthanasia was 25.2 g (range 23.5 – 
26.5) and the average tumor weight was 3.06 g (range 2.06 – 4.34). Four of the six mice that 
underwent palliative amputation demonstrated a recurrence of tumor growth at the 
amputation site. Four mice were euthanized at an average of 87 days (range 77 – 132) after 
inoculation due to a tumor score of 60. One mouse was euthanized at 16 weeks post-
inoculation in accordance with the study protocol and one mouse died in the IVIS system 91 
days after inoculation (41 days after palliative amputation). The lungs of seven mice (all six 
that underwent palliative amputation and the one mouse that did not develop a primary 
tumor) were harvested at the time of euthanasia for histological analysis (see below).
Inoculation data for Transfected Group 2
Ten mice were inoculated (5 left limbs, 5 right limbs) with the luciferase transfected K7M2 
cells to study IVIS sensitivity and detection of pulmonary metastasis using intranasal 
luciferin. The average mouse weight was 18.6 g (range 17.0 – 20.0) at the time of 
inoculation. Eight of the ten mice grew a primary tumor at an average of 23 days (range 21 – 
26) after cell implantation. Two mice failed to develop a tumor; these mice were euthanized 
sixteen weeks after inoculation. Eight mice underwent palliative amputation of the affected 
hind limb an average of 12 days (range 8 – 16) after first tumor sighting. Seven mice 
survived the palliative amputation; one mouse died due to uncontrollable hemorrhage from 
the femoral vessels. The average mouse weight at time of amputation was 23.0 g (range 20.0 
– 24.0) and the average tumor weight was 2.13 g (range 1.13 – 3.0). Seven mice were 
euthanized at an average of 57 days (range 48 – 79) after inoculation due to a tumor score of 
60. Two mice were euthanized at 16 weeks post-inoculation in accordance with the study 
protocol and one mouse died during palliative amputation. The lungs of seven mice (all 
seven that survived palliative amputation) were harvested at the time of euthanasia for 
histological analysis (see below).
Inoculation data of Transfected Group 3
Two mice were inoculated (1 left limb, 1 right limb) with the luciferase transfected K7M2 
cells to monitor luminescence and primary tumor size over time. The average mouse weight 
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was 17.0 g at the time of inoculation. Both mice grew a primary tumor at an average of 11 
days after cell implantation. These mice were imaged twice weekly until reaching a tumor 
score of 60, at which time the mice were euthanized. The lungs were not harvested for 
histological analysis.
Analysis
There were no significant differences between the WT and Transfected Group 1 with regard 
to inoculation rate, time from tumor detection to removal, tumor weight, mouse weight at 
death, or time from inoculation to time of death (any cause). There was a significant 
difference between the time of inoculation to time of tumor growth and weight of the mouse 
at time of primary tumor harvest, however. On average, it took 17.85 days longer for a 
primary tumor to develop in the transfected mice compared to the wild type strain 
(p<0.0001) and the transfected mice weighed 1.63 g more (p = 0.0175) (Table 1).
There were no significant differences between Transfected Group 1 and Transfected Group 2 
with regard to inoculation rate, time from tumor detection to removal, time from inoculation 
to death (days), metastatic rate, or IVIS positivity in histologically-confirmed metastasis. 
There was a significant difference noted between the time from inoculation to primary tumor 
detection, mouse weight at time of tumor harvest, and average primary tumor weight. On 
average, it took 12.2 days longer for a primary tumor to develop in Transfected Group 1 
compared to Group 2 (p = 0.0032). Tumors for Transfected Group 1 weighed 0.87 g more 
than tumors for Group 2(p = 0.0269) (Table 2).
Histology results
Lungs were collected on ten of the twelve WT specimens. Lungs were not collected on one 
mouse that died prior to developing a primary tumor and one mouse euthanized at the time 
of primary tumor harvest. Nine of ten specimens showed evidence of metastatic disease 
when analyzed microscopically. The number and size of metastatic nodules varied per 
mouse with a range of 1 to >10 lesions measuring 0.1 mm to 5.8 mm.
Lungs were collected on seven of ten Transfected Group 1 mice. Lungs were not collected 
on one mouse that died during IVIS imaging (prior to palliative amputation) and two mice 
euthanized at the time of primary tumor collection. Six of seven mice showed evidence of 
metastatic disease by microscopy. Again, size and number of lesions ranged from 1 to >10 
and measured 1.3 mm to 20 mm in greatest single dimension. One mouse (T17) showed 
nearly complete obliteration of native lung tissue with tumor; tumor was seen within the 
lymph nodes as well as invading the diaphragm (Figures 2a–c).
Lungs were collected on seven of ten Transfected Group 2 mice. Lungs were not collected 
on one mouse that died during palliative amputation and two mice that failed to develop a 
primary tumor. Six of seven mice showed evidence of metastatic disease by microscopy. 
Size and number of lesions ranged from 1 to >10 and measured 0.1 mm to 4.0 mm in 
greatest single dimension. Lungs were not collected for Transfected Group 3 mice.
Histologically, specimens revealed confluent sheets of poorly differentiated cells. There was 
a spectrum of cells from those with a spindle shaped appearance, prominent chromatin, and 
Grisez et al. Page 8













eosinophilic cytoplasm to those with a purely anaplastic appearance. High numbers of 
mitotic figures were appreciated. There was no statistical difference between the rate of 
metastasis between the WT and Transfected Group 1 (90% WT versus 86% transfected 
p=1.0000).
IVIS data
Seven of ten mice in Transfected Group 1 were imaged routinely by IVIS. All primary 
tumors were confirmed by presence of a bioluminescent signal from the leg region that was 
inoculated. Three mice showed evidence of a pulmonary metastatic lesion by IVIS. These 
lesions were seen on average 85.3 days (range 51 – 128) after inoculation with tumor cells. 
The smallest pulmonary lesion that was IVIS positive measured 5.3 mm microscopically. 
This mouse did not show a pulmonary lesion until 128 days after inoculation and was 
euthanized four days later (Figures 3a and 3b). The largest non-IVIS positive lesion 
measured 2.2 mm microscopically.
Seven of ten mice in Transfected Group 2 were imaged routinely by IVIS. These mice 
received intranasal and intraperitoneal luciferin, along with shaving of the operative limb 
and chest. All primary tumors were confirmed by presence of a bioluminescent signal from 
the leg region that was inoculated. Six mice showed evidence of a pulmonary metastatic 
lesion by IVIS. These lesions were seen at an average of 50 days (range 44 – 62) after 
inoculation with tumor cells. The smallest pulmonary lesion that was IVIS positive 
measured 1.4 mm microscopically. The largest non-IVIS positive lesion measured 3.8 mm 
microscopically.
The two mice in Transfected Group 3 were imaged routinely by IVIS to monitor 
luminescence and primary tumor size over time. Primary tumor was first detected on day 12 
via IVIS imaging for both mice. Primary tumor luminescent intensity increased linearly over 
time as the size of the tumor increased. There was a slight drop in intensity from day 21 to 
day 33 (Figures 4a–4c).
Discussion
Prior to 1975, osteosarcoma treatment was limited in scope and often ended in amputation. 
Advances in chemotherapeutic agents led to the widespread use of adjuvant and neo-
adjuvant therapy. Concurrent refinement of surgical technique and a paradigm shift from 
amputation to limb preserving therapy has led to an improved prognosis. Despite these 
advances, overall prognosis for osteosarcoma remains grave. The most significant challenge 
surrounding osteosarcoma is its potential for early metastasis and the nature of metastatic 
lesions that remain elusive to early detection. Indeed, it is estimated that patients presenting 
with pulmonary metastases have a five-year survival rate of less than 20%. Whereas 
chemotherapeutic agent expansion in the last 20 years has shown only minimal gains with 
regard to mortality, new avenues for treatment are actively being sought, including 
immunotherapy.
Relevant animal models are needed to examine the response of pulmonary metastases to 
various treatment agents and the primacy of an immunocompetent model cannot be 
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understated. Further, being orthotopically driven allows cell selection, self-seeding, and 
other processes to occur in vivo that may have an effect on the pathogenesis of this disease 
and, in turn, on treatment success. The resulting metastatic lesions have a unique subset of 
cellular characteristics secondary to all of these processes that take part in an orthotopic 
model. Studies recapitulated in immunocompromised animals,8–10,21–23 by inducing 
tumorigenesis via intravenous or subcutaneous cell injection, or use of a transfection method 
with antigenic vectors do not exploit these essential principles.24–25
Comparing the results of the WT cell line to Transfected Group 1, the only clinically 
significant difference between the groups was the time from inoculation to detection of 
tumor growth. On average, the transfected tumors took about twice as long to present; 
thereafter, growth rates were similar. It is not clear why this pattern occurs, but it is 
consistent with other studies our lab is conducting. We have speculated that it is likely 
resulting from the additional genetic material that must be transcribed due to insertion of the 
luciferase vector. In vitro analysis of the transfected cell line did not demonstrate a loss of 
cell viability with propagation. In vivo, inoculation rates as well as metastatic rates appear to 
be similar between the two groups and consistent with previously reported rates for this cell 
line.20 The smallest detectable lesion by IVIS measured 5.3 mm, which is larger than the 
detection limit for MRI or micro CT. However, the specificity of the lesions is 100% in this 
model because tumors from this cell line will fluoresce, whereas pulmonary nodules could 
be caused by factors other than cancer. The other advantage is the much shorter length of 
time under anesthesia as well as the anesthesia being less deep. These issues become much 
more important for survivability during testing once the animal becomes metastatic. In 
addition, IVIS is a more cost effective tool and logistically easier to perform compared to 
MRI.
With the addition of intranasal luciferin and shaving of the chest, the sensitivity of IVIS 
imaging to detect pulmonary metastasis improved. For Transfected Group 1 that did not 
receive intranasal luciferin, IVIS imaging detected a signal intensity in three out of six mice 
with histologically-positive pulmonary metastasis. With the addition of intranasal luciferin 
to Transfected Group 2, IVIS imaging detected a signal intensity in six out of seven mice 
with histologically-positive pulmonary metastasis. The sensitivity to detect pulmonary 
metastasis was 50% in Transfected Group 1 compared to an improved sensitivity of 85.7% 
in Transfected Group 2 with the addition of intranasal luciferin and shaving of the chest.
Pulmonary metastasis was also detected much earlier on IVIS with the addition of intranasal 
luciferin and shaving of the chest. On average, pulmonary metastasis was detected on IVIS 
imaging 50 days after inoculation in Transfected Group 2 compared to 85 days after 
inoculation in Transfected Group 1 that did not receive intranasal luciferin (p = 0.0568). The 
smallest pulmonary lesion that was IVIS positive measured 5.3 mm microscopically in 
Transfected Group 1 compared to 1.4 mm microscopically in Transfected Group 2. With the 
addition of intranasal luciferin and shaving, pulmonary metastasis was detected much earlier 
and with much smaller histologically sized lesions. The increased sensitivity of intranasal 
luciferin has been confirmed in previous studies, as one study showed a nearly ten-fold 
increase in sensitivity on bioluminescent imaging when comparing intranasal to 
intraperitoneal delivery of luciferin.26
Grisez et al. Page 10













The utility of IVIS imaging can also be extended to monitor temporal increases in tumor 
intensity as the size of the tumor increases. Temporal increases in tumor intensity was 
demonstrated by the data from Transfected Group 3, which showed that the tumor intensity 
(photons/second) increased linearly over time as the size of the tumor increased. There was a 
slight drop in intensity from day 21 to day 33, which likely corresponded to central tumor 
necrosis or hypoxic areas of the tumor bed as the tumor continued to grow in size. A 
depiction of potential tumor necrosis or hypoxia is well visualized in Figure 4a for mouse 
T41 at day 33. Based on these data, it seems reasonable to extend the application of IVIS 
imaging to monitor metastatic luminescence over time.
Khanna et al. reported the results of orthotopically implanted K7M2 cells in BALB/c mice.
20 They found a tumor take rate of 95% and a pulmonary metastatic rate of 93.3% with an 
average of 5.4 metastatic lesions per mouse. All mice underwent a palliative amputation of 
their affected hind limb once tumor volume reached approximately 450 mm3. Tumor latency 
(time from implantation to detection) was 14 +/− 3.1 days which is consistent with the WT 
mice in our study; however, in our study, tumors were larger and were removed, on average, 
ten days sooner. Metastases in the Khanna study were enumerated using India ink via 
intratracheal injection at the time of euthanasia instead of histology which is the clinical 
standard. In addition, they did not use a luciferase reporter making it impossible to perform 
in vivo imaging.
Sottnik and colleagues developed a luciferase transfected orthotopic model of mouse 
osteosarcoma in C3H mice using the DLM8 cell line.15 A plasmid transfection process was 
utilized. All mice underwent palliative amputation of their hind limbs at various intervals 
following implantation. They did find that amputations performed at seven days post 
implantation did not develop metastases indicating that peripheral organ seeding does not 
occur at the time of inoculation and metastatic potential requires maturation of the primary 
tumor bed. All mice amputated after day seven in their study developed metastatic disease 
by 22 days post-implantation. They did not report the rate of IVIS positive pulmonary 
lesions and did not have a non-metastatic line for comparison (the K12 cell line for the 
K7M2).
Miretti et al. developed an orthotopic lentiviral luciferase transfected K5 osteosarcoma 
model in BALB/c mice.14 They reported all mice had IVIS detectable metastatic lesions by 
45 days post-tumor implantation. The wild type and transfected cell lines had similar rates of 
primary tumor and spontaneous pulmonary disease development. They did not correlate 
tumor size by histology to the IVIS results. A potential drawback to this study is the use of a 
lentivirus transfection process which may have an effect on tumor infiltrating lymphocytes 
moreso than a plasmid vector, which was used in our study.
There are some limitations to our model. First, the K7M2 cell line is murine in origin and 
not human derived. However, the utility of murine derived tumor models is well established. 
The use of xenograft models is an alternative; however, it is known that tumor characteristics 
are influenced by the surrounding microenvironment. Thus, invasion of murine cells may 
affect the tumorigenicity. The development of metastatic disease does take time following 
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orthotopic implantation. However, the use of orthotopic models most closely mimics the 
clinical course of cancer progression in this disease.
This study establishes a new murine model for metastatic osteosarcoma in an 
immunocompetent mouse using the K7M2-wt highly metastatic cell line transfected with a 
non-viral plasmid luciferase vector. Bioluminescence and histopathology confirmed the 
establishment of a primary tumor and metastasis to the lungs. The sensitivity of IVIS 
imaging was determined by comparison of histopathological analysis of the lungs. To our 
knowledge, this is the first syngeneic osteosarcoma using the K7M2 cell line that uses 
bioluminescence to survey and quantify metastatic burden. The primary benefit of the 
preclinical model is that the immune system is intact, metastatic disease is orthotopically 
driven, and it appears to have a comparable pathogenesis to its wild type counterpart. The 
model can be used to examine promising immunomodulatory therapies in the future using 
bioluminescence in vivo.
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Figure 1a demonstrates extensive recurrent tumor growth after palliative amputation. No 
pulmonary lesions appear to be present, although T13 (middle) had evidence of a pulmonary 
lesion a week prior (not shown). Figure 1b shows bioluminescent signal consistent with 
pulmonary metastasis after shielding of the lower extremities. The images were taken 
sequentially the same day.
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Figure 2a illustrates extensive pulmonary metastatic disease by IVIS. At necropsy, 
widespread disease was found with near total obliteration of the chest cavity with tumor 
(Figure 2b). Histologically, the classic spindle cell morphology is appreciated, with tumor 
invading the diaphragm (Figure 2c).
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Figure 3a show that, at128 days post-inoculation, a bioluminescent signal was detected in 
the pulmonary region of mouse T16. This lesion (Figure 3b) measured 5.3 mm histologically 
and was the smallest IVIS positive lesion.
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Figure 4a illustrates temporal changes in luminescent intensity over time in transfected mice 
T41 and T42. Figure 4b shows a linear representation of the primary tumor luminescence 
and tumor size over time for mice T41 and T42.
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Table 1
Summary of tumor characteristics comparing the wild type and transfected cell lines.
Wild Type Transfected P-Value
Inoculation Rate 11/12 9/10 1.0000
Time from Inoculation to Primary Tumor Detection (Days) 16.8 ± 2.0 34.7 ± 2.2 <0.0001*
Time from Detection of Primary Tumor to Tumor Removal (Days) 11.91 ± 0.8 12.5 ± 1.0 0.6526
Mouse Weight at Time of Tumor Harvest (g) 23.6 ± 0.4 25.2 ± 0.5 0.0175*
Average Primary Tumor Weight (g) 2.7 ± 0.3 3.1 ± 0.3 0.4490
Time from Inoculation to Death (Days) 67.5 ± 10.2 81.33 ± 11.2 0.3748
Average Weight at Death 24.35 ± 0.9 24.19 ± 1.0 0.9053
Metastatic Rate 9/10 6/7 1.0000













Grisez et al. Page 19
Table 2
Summary of tumor characteristics comparing Transfected Groups 1 and 2.
Transfected Group 1 Transfected Group 2 P-value
Inoculation Rate 9/10 8/10 0.5921
Time from Inoculation to Primary Tumor Detection (Days) 34.7 ± 2.2 22.5 ± 2.6 0.0032*
Time from Detection of Primary Tumor to Tumor Removal (Days) 12.5 ± 1.0 12.1 ± 1.2 0.8299
Mouse Weight at Time of Tumor Harvest (g) 25.2 ± 0.5 22.6 ± 0.5 0.0037*
Average Primary Tumor Weight (g) 3.06 ± 0.26 2.19 ± 0.24 0.0269*
Time from Inoculation to Death (Days) 85.33 ± 12.6 50.17 ± 8.9 0.0568
Metastatic Rate 6/7 6/7 1.0000
IVIS positivity in histologically-confirmed mets 3/6 6/7 0.2127
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